Yahoo Finance·2026-02-26 22:00Industry Overview - The weight-loss drug market has seen significant growth and is projected to continue expanding, indicating that it has not yet peaked [1] - The market presents opportunities for both established companies and smaller biotech firms [1] Company Analysis: Altimmune - Altimmune is a smaller biotech company aiming to enter the weight-loss drug market with its leading candidate, pemvidutide, which acts as a dual GLP-1/glucagon receptor agonist [5] - In 2023, Altimmune reported data from a phase 2 clinical trial for pemvidutide, showing strong efficacy but also high patient discontinuation rates due to adverse reactions [5] - Altimmune is also exploring pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol use disorder, with mixed results from phase 2 studies [6] - The drug met its primary endpoint for MASH resolution but did not show statistically significant improvement in fibrosis compared to placebo, leading to a decline in Altimmune's stock [6] Company Analysis: Novo Nordisk - Novo Nordisk, a leading pharmaceutical company, has faced challenges in the weight-loss market, losing ground to competitor Eli Lilly [7] - The company has had to lower its revenue guidance multiple times and now anticipates a decline in revenue for the year [7] - Novo Nordisk has encountered clinical setbacks with promising candidates and has reduced medicine prices due to government interventions, negatively impacting its stock performance [7]